Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Blood

Volumn 129, Issue 18, 2017, Pages 2471-2478

  Herbaux, Charles ^a   Gauthier, Jordan ^a   Brice, Pauline ^b   Drumez, Elodie ^c   Ysebaert, Loic ^d   Doyen, Hélène ^e   Fornecker, Luc ^f   Bouabdallah, Krimo ^g   Manson, Guillaume ^h   Ghesquières, Hervé ⁱ   Tabrizi, Reza ^j   Hermet, Eric ^k   Lazarovici, Julien ^l   Thiebaut Bertrand, Anne ^m   Chauchet, Adrien ⁿ   Demarquette, Hélène ^a   Boyle, Eileen ^a   Houot, Roch ^h   Yakoub Agha, Ibrahim ^a,o   Morschhauser, Franck ^a,p  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Section of Radiology   (France)

^c UNIV LILLE   (France)

^d Serv d'Hematologie de l'Enfant   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ Unicancer   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^o UNIVERSITÉ DE LILLE   (France)

^p Univ Lille   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CEREBELLAR ATAXIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATIC CYTOLYSIS; HODGKIN DISEASE; HUMAN; LIVER DISEASE; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

ADULT; ALLOGRAFTS; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 85017605526     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-749556     Document Type: Article

References (26)

1. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310-317.
2. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938-947.
3. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521-528.
4. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
5. Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49(2):190-194.
6. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
7. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online ahead of print 27 June 2016]. J Clin Oncol. doi:10.1200/JCO.2016.67.3467.
8. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272-1277.
9. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(17):3062-3073.
10. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581-1588.
11. Davids MS, Kim HT, Bachireddy P, et al; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143-153.
12. Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(3):443-445.
13. Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(6):850-852.
14. Villasboas JC, Ansell SM, Witzig TE. Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget. 2016;7(11):13260-13264.
15. Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
16. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
18. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.
19. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013;31(5):e59-e63.
20. Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(10):1313-1317.
21. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist. 2015;20(3):323-328.
22. Sala E, Crocchiolo R, Gandolfi S, et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1444-1447.
23. Anderlini P, Saliba R, Acholonu S, et al. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012;53(6):1239-1241.
24. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol. 2011;29(8):971-978.
25. Anastasia A, Carlo-Stella C, Corradini P, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166(1):140-142.
26. Fujiwara H, Maeda Y, Kobayashi K, et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol. 2014;193(5):2565-2573.